Results 21 to 30 of about 193,906 (268)
Resveratrol is a class IA phosphoinositide 3-kinase inhibitor [PDF]
Biochemical Journal, 2007 Resveratrol, a polyphenol found in fruits, possesses chemopreventive and chemotherapeutic properties and has been shown to increase lifespan in yeast and metazoans, including mice. Genetic evidence and in vitro enzymatic measurements indicate that the deacetylase Sir2/SIRT1, an enzyme promoting stress resistance and aging, is the target of resveratrol.
Fröjdö, Sara +3 more
openaire +4 more sources
Overview of Research into mTOR Inhibitors
Molecules, 2022 The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that belongs to the phosphoinositide 3-kinase (PI3K)-related kinase (PIKK) family.
Beibei Mao +5 more
doaj +1 more source
Immunodeficiency due to a novel variant in PIK3CD: a case report
Pediatric Rheumatology Online Journal, 2023 Background Primary immunodeficiencies are immunological disorders caused by gene mutations involved in immune system development and activation. Recently, activated phosphoinositide 3-kinase delta syndrome (APDS) due to mutations in the phosphoinositide ...
Niloofar Shashaani +6 more
doaj +1 more source
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies
Haematologica, 2014 The phosphoinositide 3-kinase pathway represents an important anticancer target because it has been implicated in cancer cell growth, survival, and motility. Recent studies show that PI3K may also play a role in the development of resistance to currently
Elias Jabbour +3 more
doaj +1 more source
Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase [PDF]
Trends in Pharmacological Sciences, 2013 Phosphoinositide (PI) 3-kinases are essential regulators of cellular proliferation, survival, metabolism, and motility that are frequently dysregulated in human disease. The design of inhibitors to target the PI 3-kinase/mTOR pathway is a major area of investigation by both academic laboratories and the pharmaceutical industry.
Hashem A, Dbouk, Jonathan M, Backer
openaire +2 more sources
Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling [PDF]
International Journal of Molecular Sciences, 2020 Signaling pathways regulated by the phosphoinositide 3-kinase (PI3K) enzymes have a well-established role in cancer development and progression. Over the past 30 years, the therapeutic potential of targeting this pathway has been well recognized, and this has led to the development of a multitude of drugs, some of which have progressed into clinical ...
Tania Maffucci, Marco Falasca
openaire +3 more sources
CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers
Zhongliu Fangzhi Yanjiu, 2019 Cyclin-dependent kinases (CDKs) inhibitors have been approved in the combination with hormone-based therapy for advanced breast cancer. In addition to endocrine therapy, the combinations of CDK4/6 inhibitors with epidermal growth factor receptor (EGFR ...
ZHANG Baihong, YUE Hongyun
doaj +1 more source
eLife, 2021 Class I Phosphoinositide 3-kinases (PI3Ks) are master regulators of cellular functions, with the class IB PI3K catalytic subunit (p110γ) playing key roles in immune signalling.
Manoj K Rathinaswamy +8 more
doaj +1 more source
Tumor Biology, 2017 In this study, we investigated the underlying mechanism of the phosphoinositide 3-kinase/Akt– and Wnt/β-catenin-mediated promotion of epithelial-to-mesenchymal transition by epigenetic regulation of histone acetylation in gastric cancer.
Yue Song +5 more
doaj +1 more source
The Treatment of Activated PI3Kδ Syndrome
Frontiers in Immunology, 2018 Activated phosphoinositide 3-kinase δ syndrome (APDS), also known as PASLI disease (p110d-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency) are combined immunodeficiencies resulting from gain-of-function mutations in ...
Tanya I. Coulter, Andrew J. Cant
doaj +1 more source